Nexus Surgical and Medicare Ltd Downgraded to Strong Sell Amid Technical and Valuation Concerns

Quality Assessment: Weakening Fundamentals Amid Flat Quarterly Performance

Nexus Surgical’s fundamental quality has come under pressure, primarily due to its flat financial performance in the third quarter of the fiscal year 2025-26. The company’s operating profits have exhibited a modest compound annual growth rate (CAGR) of just 3.19%, signalling limited expansion in core earnings. While the return on equity (ROE) remains robust at 41.7%, this metric is overshadowed by the company’s stagnant quarterly results and lack of significant growth catalysts.

Moreover, the company’s shareholder base is dominated by non-institutional investors, which may limit the availability of strategic capital and reduce market confidence. The weak long-term fundamental strength has contributed to the downgrade, as Nexus Surgical struggles to demonstrate consistent operational improvement in a competitive NBFC landscape.

Valuation: Expensive Multiples Despite Discount to Peers

Valuation metrics present a mixed picture. Nexus Surgical trades at a price-to-book (P/B) ratio of 6.5, which is considered very expensive relative to typical NBFC valuations. This high P/B ratio suggests that the market has priced in significant growth expectations, which the company has yet to fulfil given its flat recent performance.

However, the stock is currently trading at a discount compared to its peers’ historical average valuations, indicating some relative value. The price-to-earnings growth (PEG) ratio stands at 0.7, which is below 1.0 and typically signals undervaluation relative to earnings growth. Despite this, the valuation premium implied by the P/B ratio and the company’s micro-cap status raise concerns about liquidity and price volatility.

Financial Trend: Flat Quarterly Results and Mixed Returns

The financial trend for Nexus Surgical has been largely flat in the near term. The company reported no significant growth in profits for the quarter ending December 2025, which contrasts with an 11% rise in profits over the past year. This disconnect between quarterly stagnation and annual profit growth highlights volatility in earnings momentum.

Examining stock returns relative to the Sensex reveals further challenges. Over the past week and month, Nexus Surgical’s stock has underperformed the benchmark, with returns of -5.43% and -6.02% respectively, compared to Sensex declines of -1.87% and -8.51%. Year-to-date, the stock has lost 5.43%, while the Sensex has fallen 11.67%. Over longer horizons, the company has delivered exceptional returns, with a 5-year return of 376.95% versus Sensex’s 55.39%, and a 3-year return of 64.68% compared to 30.85% for the index. However, the 10-year return is negative at -66.87%, contrasting sharply with the Sensex’s 197.08% gain, underscoring inconsistent long-term performance.

Technical Analysis: Shift from Mildly Bullish to Sideways and Bearish Signals

The most significant driver behind the downgrade is the deterioration in technical indicators. Nexus Surgical’s technical grade has shifted from mildly bullish to sideways, reflecting a loss of upward momentum. Key technical metrics present a mixed and somewhat bearish outlook:

• MACD: Weekly readings remain bullish, but monthly signals have turned mildly bearish, indicating weakening momentum over longer periods.
• RSI: The weekly Relative Strength Index is bearish, suggesting selling pressure, while the monthly RSI shows no clear signal.
• Bollinger Bands: Both weekly and monthly bands indicate bearish trends, pointing to increased volatility and downward pressure.
• Moving Averages: Daily moving averages remain mildly bullish, but this is insufficient to offset broader negative signals.
• KST (Know Sure Thing): Weekly KST is bullish, but monthly readings are mildly bearish, reinforcing the mixed technical picture.
• Dow Theory: Weekly data is mildly bearish, with no clear trend on the monthly scale.

These conflicting signals have culminated in a sideways technical trend, undermining investor confidence and prompting the MarketsMOJO rating downgrade to Strong Sell with a Mojo Score of 27.0. The stock’s day change of -2.36% and current price of ₹16.55, down from a previous close of ₹16.95, further reflect this technical weakness.

Market Capitalisation and Peer Comparison

Nexus Surgical is classified as a micro-cap stock, which inherently carries higher risk due to lower liquidity and greater price volatility. Despite its expensive valuation metrics, the stock’s discount to peer historical valuations offers a limited cushion. The company’s performance relative to the broader NBFC sector and Sensex index highlights the challenges it faces in sustaining growth and investor interest.

Conclusion: Downgrade Reflects Technical Weakness and Valuation Risks Amid Flat Growth

The downgrade of Nexus Surgical and Medicare Ltd to a Strong Sell rating by MarketsMOJO is primarily driven by a shift in technical indicators from mildly bullish to sideways and bearish signals, combined with expensive valuation multiples and flat recent financial performance. While the company boasts a strong ROE and has delivered impressive long-term returns over five years, its recent quarterly stagnation and mixed technical outlook have eroded investor confidence.

Investors should exercise caution given the stock’s micro-cap status, valuation concerns, and the predominance of non-institutional shareholders. The current market environment and technical signals suggest limited upside potential in the near term, making Nexus Surgical a less attractive option compared to other NBFC peers and broader market opportunities.

Monitoring the company’s ability to revive growth and improve technical momentum will be crucial for any future rating upgrades. Until then, the Strong Sell rating reflects a prudent stance based on comprehensive analysis of quality, valuation, financial trends, and technical factors.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today